Anteris Technologies Global Corp. CHESS Depositary Interest (AVR) represents ownership in Anteris Technologies Global Corp., a structural heart company focused on developing and commercializing minimally invasive medical devices for heart valve diseases. These CHESS Depositary Interests (CDIs) are listed on the Australian market and are designed to provide Australian investors with exposure to the company’s US-listed common stock, with a 1:1 conversion ratio. Anteris is known for its innovative DurAVR transcatheter heart valve system, which mimics the performance of a healthy human aortic valve, and its ADAPT anti-calcification tissue technology. The company operates globally, with significant research and commercial activities in the United States, Australia, and Europe. AVR CDIs enable investors to participate in the growth of a pioneering medical device firm at the forefront of cardiac care innovation.